Subcutaneous abatacept in rheumatoid arthritis: current update

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Biologic agents have transformed rheumatoid arthritis (RA) therapy.
• Intravenous abatacept (ABA) selectively inhibits T-cell and antigen-presenting cell interactions.
• Subcutaneous ABA is now also approved for RA treatment.

Purpose of the Study:

• To review recent clinical data on abatacept for RA.
• To evaluate the efficacy and safety of subcutaneous ABA.
• To compare subcutaneous ABA with intravenous ABA and other biologics.

Main Methods:

• Review of Phase III clinical trials (ACQUIRE, ACCOMPANY, ALLOW, ATTUNE, AMPLE, AVERT).
• Assessment of clinical efficacy, including long-term outcomes.
• Evaluation of radiographic progression, safety, and immunogenicity.

Main Results:

• Subcutaneous ABA demonstrates comparable efficacy to intravenous ABA.
• Safety profiles of intravenous and subcutaneous ABA are similar.
• Both formulations show good safety records in RA treatment.

Conclusions:

• The availability of both intravenous and subcutaneous ABA offers significant advantages.
• Subcutaneous administration aligns with the trend in biologic therapy.
• Clinical trials confirm comparable efficacy and safety for subcutaneous ABA.